ADHANSIA Canadian Trademark Information

On Tuesday, April 25, 2017, a canadian trademark registration was filed for ADHANSIA by PURDUE PHARMA *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1834376. The current status of this trademark filing is Registration published. The ADHANSIA trademark is filed in the description of Pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, cognitive impairment disorders, mood disorders, oppositional defiance disorder, conduct disorder, learning disabilities, autism spectrum disorder, tic disorders, binge eating and obsessive eating disorders, anxiety disorders, substance abuse disorders, depression, psychosis , Providing information to health care providers about pharmaceutical preparations, including pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, via a website, the Internet or other global communication networks; providing information to health care providers about pharmaceutical preparations, including pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system , Pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system; pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, cognitive impairment disorders, mood disorders, oppositional defiance disorder, conduct disorder, learning disabilities, autism spectrum disorder, tic disorders, binge eating and obsessive eating disorders, anxiety disorders, substance abuse disorders, depression, psychosis , Pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, namely, attention deficit disorder, attention deficit hyperactivity disorder, hyperactivity, cognitive impairment disorders, mood disorders, oppositional defiance disorder, conduct disorder, learning disabilities, autism spectrum disorder, tic disorders, binge eating and obsessive eating disorders, anxiety disorders, substance abuse disorders, depression, psychosis , Providing information to health care providers about pharmaceutical preparations, including pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system, via a website, the Internet or other global communication networks; providing information to health care providers about pharmaceutical preparations, including pharmaceutical preparations for the treatment of diseases and disorders of the central nervous system .